Table 1 Baseline clinical characteristics of maintenance hemodialysis patients stratified into sacubitril valsartan and control groups
|  | SV (n = 59) | Control (n = 59) | p/x2 |
|---|---|---|---|
Age (years) | 59.94 ± 12.64 | 58.81 ± 12.31 | 0.9 |
Sex, n (%) | Â | Â | 0.2 |
 Male  Female | 41 (69.49) 18 (30.51) | 51 (57.89) 24 (42.11) | -- -- |
BMI SBP DBP | 22.77 ± 3.27 151.71 ± 21.21 81.71 ± 13.31 | 23.94 ± 4.96 145.72 ± 20.17 81.30 ± 13.38 | 0.07 0.2 0.8 |
ADQI class for HF - n (%) | Â | Â | 0.2 |
 2R-2NR  3R-3NR  4R-4NR | 35 (59.32) 16 (27.12) 8 (13.56) | 42 (72.41) 16 (27.59) 0 | -- -- -- |
Baseline disease-n (%) | Â | Â | Â |
 Hypertension  Diabetes | 52 (88.13) 23 (38.98) | 51 (87.93) 22 (37.93) | 0.9 0.9 |
HD vintage (months) | 52 (24, 63) | 55 (27, 83) | 0.4 |
Smoking history-n (%) | 32 (54.23) | 24 (40.68) | 0.2 |
UF (L) | 2.74 ± 0.76 | 2.91 ± 0.85 | 0.2 |
Scr (umol/L) | 881.84 ± 245.38 | 876.09 ± 245.38 | 0.9 |
BUN | 21.96 ± 6.29 | 22.29 ± 6.30 | 0.8 |
eGFR (CKD-EPI) | 4.96 ± 0.89 | 4.75 ± 1.01 | 0.8 |
Alb (g/L) | 40.14 ± 1.66 | 4.56 ± 4.09 | 0.6 |
K (mmol/L)) | 4.98 ± 0.71 | 4.99 ± 0.72 | 0.9 |
Na (mmol/L) | 140.20 ± 3.55 | 141.30 ± 3.87 | 0.9 |
Cl (mmol/L) | 103.70 ± 8.72 | 105.10± 8.46 | 0.7 |
Ca (mmol/L) | 2.29 ± 0.16 | 2.32 ± 0.20 | 0.4 |
P (mmol/L) | 1.75 ± 0.50 | 1.86 ± 0.52 | 0.2 |
hs-CRP (mg/L) | 2.00 (1.00-3.40) | 1.80 (1.00–3.60) | 0.5 |
LDL (mmol/L) | 1.98 ± 0.75 | 2.26 ± 0.76 | 0.7 |
TC (mmol/L) | 3.56 ± 0.90 | 3.90 ± 1.09 | 0.2 |
Antihypertensive medicines – n (%) |  |  | 0.5 |
 RASI | 40 (67.80) | 41 (70.83) |  |
 BB  CCB  αB | 35 (59.32) 47 (79.66) 17 (28.81) | 30 (51.04) 47 (81.25) 10 (16.67) | -- -- -- |